Literature DB >> 27526964

Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

K Lahdensuo1, A Rannikko1, V-J Anttila2, A Erickson3, A Pätäri-Sampo4, M Rautio4, H Santti1, E Tarkka4, M Vaara4, K Huotari2.   

Abstract

BACKGROUND: The most severe manifestations of prostate biopsy complications are bacteremic infections. These complications are increasing alarmingly.
METHODS: A retrospective cohort study of 17 183 transrectal prostate biopsies performed at the Helsinki and Uusimaa hospital district in southern Finland during 2005-2013. Biopsies were linked to a database of positive blood cultures, yielding 111 bacteremic cases, and yearly bacteremia rates were determined. By multiple regression analysis, demographic risk factors of the whole biopsy cohort for developing bacteremia or fluoroquinolone (FQ)-resistant bacteremia were studied. Clinical risk factors for bacteremia caused by an FQ-resistant organism and for serious bacteremic outcomes were studied by univariate and multivariate analyzes.
RESULTS: The average bacteremia rate was 0.7% (111 of 17 183 biopsies) and an increase was observed from 0.5% in 2005 (95% confidence interval (CI): 0.3-0.9) to 1.2% in 2012 (95% CI 0.8-1.8); 53.2% were caused by an FQ-resistant organism. In univariate regression analysis, previous biopsy sessions and increasing calendar year of biopsy associated with the risk of developing bacteremia (odds ratio (OR) 1.232, 95% CI: 1.020-1.488, P=0.030 and OR 1.164, 95% CI: 1.079-1.255, P<0.001, respectively), but only increasing calendar year of biopsy remained statistically significant (OR 1.155, 95% CI: 1.070-1.247, P<0.001) in multivariate analysis. Foreign travel within 3 months was associated with FQ resistance in multivariate analysis (OR 7.158, 95% CI: 1.042 to infinite, P=0.045). The study failed to show any significant clinical risk factors for serious bacteremic outcomes (requiring intensive care, developing deep infection foci or death).
CONCLUSIONS: The postbiopsy bacteremia rate doubled during the study period and half of the cases were caused by FQ-resistant organisms. Recent foreign travel increased the risk for FQ resistance. Future research efforts should be aimed at better identifying risk factors, targeted prophylaxis and reducing the need for biopsies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27526964     DOI: 10.1038/pcan.2016.36

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  32 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  Modification of antimicrobial prophylaxis based on rectal culture results to prevent fluoroquinolone-resistant Escherichia coli infections after prostate biopsy.

Authors:  Nuntra Suwantarat; Donald M Dumford; Rafael Ponce-Terashima; Sirisha Kundrapu; Trina F Zabarsky; Hui Zhu; Curtis J Donskey
Journal:  Infect Control Hosp Epidemiol       Date:  2013-07-29       Impact factor: 3.254

3.  Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis.

Authors:  Michael A Liss; William Kim; Dena Moskowitz; Richard J Szabo
Journal:  J Urol       Date:  2015-04-03       Impact factor: 7.450

4.  Bacterial sepsis following prostatic biopsy.

Authors:  Luca Carmignani; Stefano Picozzi; Matteo Spinelli; Salvatore Di Pierro; Gabriella Mombelli; Ercole Negri; Milvana Tejada; Paola Gaia; Elena Costa; Augusto Maggioni
Journal:  Int Urol Nephrol       Date:  2012-02-28       Impact factor: 2.370

5.  Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care.

Authors:  Aisha K Taylor; Teresa R Zembower; Robert B Nadler; Marc H Scheetz; John P Cashy; Diana Bowen; Adam B Murphy; Elodi Dielubanza; Anthony J Schaeffer
Journal:  J Urol       Date:  2012-02-16       Impact factor: 7.450

6.  Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.

Authors:  Robert K Nam; Refik Saskin; Yuna Lee; Ying Liu; Calvin Law; Laurence H Klotz; D Andrew Loblaw; John Trachtenberg; Aleksandra Stanimirovic; Andrew E Simor; Arun Seth; David R Urbach; Steven A Narod
Journal:  J Urol       Date:  2013-01       Impact factor: 7.450

7.  Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.

Authors:  Leonard P Bokhorst; Arnout R Alberts; Antti Rannikko; Riccardo Valdagni; Tom Pickles; Yoshiyuki Kakehi; Chris H Bangma; Monique J Roobol
Journal:  Eur Urol       Date:  2015-06-29       Impact factor: 20.096

8.  Clinical and microbiological determinants of infection after transrectal prostate biopsy.

Authors:  Michael A Liss; James R Johnson; Stephen B Porter; Brian Johnston; Connie Clabots; Kyle Gillis; Unwanaobong Nseyo; Marc Holden; Kyoko Sakamoto; Joshua Fierer
Journal:  Clin Infect Dis       Date:  2014-12-16       Impact factor: 9.079

9.  Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy.

Authors:  Kaylee Marino; Anne Parlee; Ralph Orlando; Lori Lerner; Judith Strymish; Kalpana Gupta
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

10.  Association between pre-biopsy white blood cell count and prostate biopsy - related sepsis.

Authors:  Suleyman Bulut; Binhan Kagan Aktas; Cevdet Serkan Gokkaya; Alp Ozgur Akdemir; Akif Ersoy Erkmen; Mehmet Karabakan; Ali Memis
Journal:  Cent European J Urol       Date:  2015-03-13
View more
  4 in total

1.  Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.

Authors:  Inari Kalalahti; Kaisa Huotari; Kanerva Lahdensuo; Eveliina Tarkka; Henrikki Santti; Antti Rannikko; Anu Pätäri-Sampo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-02       Impact factor: 3.267

2.  Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach.

Authors:  Bettina Wulff Risør; Nasrin Tayyari Dehbarez; Jacob Fredsøe; Karina Dalsgaard Sørensen; Bodil Ginnerup Pedersen
Journal:  Appl Health Econ Health Policy       Date:  2022-08-08       Impact factor: 3.686

3.  The effectiveness of targeted relative to empiric prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy: a meta-analysis.

Authors:  Susan Scott; Patrick N Harris; Deborah A Williamson; Michael A Liss; Suhail A R Doi; Matthew J Roberts
Journal:  World J Urol       Date:  2018-02-16       Impact factor: 4.226

Review 4.  Rethinking prostate cancer screening: could MRI be an alternative screening test?

Authors:  David Eldred-Evans; Henry Tam; Heminder Sokhi; Anwar R Padhani; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Urol       Date:  2020-07-21       Impact factor: 14.432

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.